Hubbry Logo
CryptorchidismCryptorchidismMain
Open search
Cryptorchidism
Community hub
Cryptorchidism
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Cryptorchidism
Cryptorchidism
Cryptorchidism
View on Wikipedia
from Wikipedia
Cryptorchidism
Cryptorchidism on scrotal ultrasound
SpecialtyMedical genetics Edit this on Wikidata

Cryptorchidism, also known as undescended testis (UDT), is the failure of one or both testicles to descend into the scrotum. The word is from Ancient Greek κρυπτός (kryptos) 'hidden' and ὄρχις (orchis) 'testicle'. It is the most common birth defect of the male genital tract.[1] About 3% of full-term and 30% of premature infant boys are born with at least one undescended testis.[2] However, about 80% of cryptorchid testes descend by the first year of life (the majority within three months), making the true incidence of cryptorchidism around 1% overall. Cryptorchidism may develop after infancy, sometimes as late as young adulthood, but that is exceptional.

Different forms of cryptorchidism, depending on the position of the undescended testicle. Sometimes the retractile testicle is added.

Cryptorchidism is distinct from monorchism, the condition of having only one testicle. Though the condition may occur on one or both sides, it more commonly affects the right testis.[3]

A testis absent from the normal scrotal position may be:

  1. Anywhere along the "path of descent" from high in the posterior (retroperitoneal) abdomen, just below the kidney, to the inguinal ring
  2. In the inguinal canal
  3. Ectopic, having "wandered" from the path of descent, usually outside the inguinal canal and sometimes even under the skin of the thigh, the perineum, the opposite scrotum, or the femoral canal
  4. Undeveloped (hypoplastic) or severely abnormal (dysgenetic)
  5. Missing (also see anorchia).

About two-thirds of cases without other abnormalities are unilateral; most of the other third involve both testes. In 90% of cases, an undescended testis can be felt in the inguinal canal. In a small minority of cases, missing testes may be found in the abdomen or appear to be nonexistent (truly "hidden").

Undescended testes are associated with reduced fertility, increased risk of testicular germ-cell tumors, and psychological problems when fully-grown. Undescended testes are also more susceptible to testicular torsion (and subsequent infarction) and inguinal hernias.[citation needed] Without intervention, an undescended testicle will usually descend during the first year of life, but to reduce these risks, undescended testes can be brought into the scrotum in infancy by a surgical procedure called an orchiopexy.[4]

Although cryptorchidism nearly always refers to congenital absence or maldescent, a testis observed in the scrotum in early infancy can occasionally "reascend" (move back up) into the inguinal canal. A testis that can readily move or be moved between the scrotum and canal is referred to as retractile.

Cryptorchidism, hypospadias, testicular cancer, and poor semen quality make up the syndrome known as testicular dysgenesis syndrome.

Signs and symptoms

[edit]

Infertility

[edit]

Many men who were born with undescended testes have reduced fertility, even after orchiopexy in infancy. The reduction with unilateral cryptorchidism is subtle, with a reported infertility rate of about 10%, compared with about 6% reported by the same study for the general population of adult men.

The fertility reduction after orchiopexy for bilateral cryptorchidism is more marked, about 38%, or six times that of the general population. The basis for the universal recommendation for early surgery is research showing degeneration of spermatogenic tissue and reduced spermatogonia counts after the second year of life in undescended testes. The degree to which this is prevented or improved by early orchiopexy is still uncertain.

Cancer risk

[edit]

One of the strongest arguments for early orchiopexy is reducing the risk of testicular cancer. About one in 500 men born with one or both testes undescended develop testicular cancer, roughly a four- to 40-fold increased risk. The peak incidence occurs in the third and fourth decades of life. The risk is higher for intra-abdominal testes and somewhat lower for inguinal testes, but even the normally descended testis of a man whose other testis was undescended has about a 20% higher cancer risk than those of other men.[citation needed]

The most common type of testicular cancer occurring in undescended testes is seminoma.[5] It is usually treatable if caught early, so urologists often recommend that boys who had orchiopexy as infants be taught testicular self-examination, to recognize testicular masses and seek early medical care for them. Cancer developing in an intra-abdominal testis would be unlikely to be recognized before considerable growth and spread, and one of the advantages of orchiopexy is that a mass developing in a scrotal testis is far easier to recognize than an intra-abdominal mass.

Orchidopexy was originally thought to result in easier detection of testicular cancer, but it did not lower the risk of actually developing cancer. However, recent data have shown a paradigm shift. The New England Journal of Medicine published in 2007, that orchidopexy performed before puberty resulted in a significantly reduced risk of testicular cancer than if done after puberty.[6]

The risk of malignancy in the undescended testis is 4 to 10 times higher than that in the general population and is about one in 80 with a unilateral undescended testis and one in 40 to one in 50 for bilateral undescended testes. The peak age for this tumor is 15–45 years old. The most common tumor developing in an undescended testis is a seminoma (65%); in contrast, after orchiopexy, seminomas represent only 30% of testicular tumors.[7]

Causes

[edit]

Environmental hypotheses

[edit]

In most full-term infant boys with cryptorchidism but no other genital abnormalities, a cause cannot be found, making this a common, sporadic, unexplained (idiopathic) birth defect. A combination of genetics, maternal health, and other environmental factors may disrupt the hormones and physical changes that influence the development of the testicles.

  • Severely premature infants can be born before the descent of the testes. Low birth weight is also a known factor.[8]
  • A contributing role of environmental chemicals called endocrine disruptors that interfere with normal fetal hormone balance has been proposed. The Mayo Clinic lists "parents' exposure to some pesticides" as a known risk factor.[8][9]
  • Risk factors may include exposure to regular alcohol consumption during pregnancy (five or more drinks per week, associated with a three-fold increase in cryptorchidism when compared to nondrinking mothers.[10] Cigarette smoking is also a known risk factor.[8]
  • Family history of undescended testicles or other problems of genital development[8]
  • Cryptorchidism occurs at a much higher rate in a large number of congenital malformation syndromes. Among the more common are Down syndrome,[8] Prader–Willi syndrome, and Noonan syndrome.
  • In vitro fertilization, use of cosmetics by the mother, and pre-eclampsia have also been recognized as risk factors for the development of cryptorchidism.[11]
  • Androgen insensitivity syndrome generally manifests itself in Cryptorchidism. In CAIS, the testis are generally located completely undescended, where the ovaries usually are. In PAIS, the testis is generally partially undescended. This also occurs with 5α-Reductase 2 deficiency (DHT insensitivity) however, the testis generally descend during puberty.

In 2008, a study was published that investigated the possible relationship between cryptorchidism and prenatal exposure to a chemical called phthalate (DEHP), which is used in the manufacture of plastics. The researchers found a significant association between higher levels of DEHP metabolites in pregnant mothers and several sex-related changes, including incomplete descent of the testes in their sons. According to the lead author of the study, a national survey found that 25% of U.S. women had phthalate levels similar to the levels that were found to be associated with sexual abnormalities.[12]

A 2010 study examined the prevalence of congenital cryptorchidism among offspring whose mothers had taken mild analgesics, primarily over-the-counter pain medications including ibuprofen (e.g. Advil) and paracetamol (acetaminophen).[13] Combining the results from a survey of pregnant women prior to their due date in correlation with the health of their children and an ex vivo rat model, the study found that pregnant women who had been exposed to mild analgesics had a higher prevalence of baby boys born with congenital cryptorchidism.[13]

New insight into the testicular descent mechanism has been hypothesized by the concept of a male programming window derived from animal studies. According to this concept, testicular descent status is "set" during the period from 8 to 14 weeks of gestation in humans. Undescended testis is a result of disruption in androgen levels only during this programming window.[14]

Sexually antagonistic epigenetic marker hypothesis

[edit]

When one identical twin is born with cryptorchidism, his identical twin also has the trait only 25% of the time, despite sharing their genes and prenatal hormonal environment.[15] Animal studies have found that androgen antagonists during early fetal development cause elevated rates of hypospadias and cryptorchidism, however, in humans these traits rarely occur together.[15] In addition, levels of circulating testosterone overlap for both male and female fetuses throughout fetal development. Rice et al. have proposed that sexually dimorphic development occurs through epigenetic markers which are laid down during stem cell development, which blunt androgen signalling in XX fetuses, and boost sensitivity in XY fetuses.[16] If these marks are sexually antagonistic, and if a subset of these epigenetic marks carry over generations, they are expected to produce mosaicism of sexual development in opposite-sex offspring, sometimes producing hypospadias or cryptorchidism when passed from a mother to son (feminizing the external genitalia). Rice's model requires further testing with currently available technology to support or falsify it.[16]

Mechanism

[edit]

Normal development

[edit]

The testes begin as an immigration of primordial germ cells into testicular cords along the gonadal ridge in the abdomen of the early embryo. The interaction of several male genes organizes this developing gonad into a testis rather than an ovary by the second month of gestation. During the third to fifth months, the cells in the testes differentiate into testosterone-producing Leydig cells, and anti-Müllerian hormone-producing Sertoli cells. The germ cells in this environment become fetal spermatogonia. Male external genitalia develop during the third and fourth months of gestation, and the fetus continues to grow, develop, and differentiate. The testes remain high in the abdomen until the seventh month of gestation, when they move from the abdomen through the inguinal canals into the two sides of the scrotum. Movement has been proposed to occur in two phases, under the control of somewhat different factors. The first phase, movement across the abdomen to the entrance of the inguinal canal, appears controlled (or at least greatly influenced) by anti-Müllerian hormone (AMH). The second phase, in which the testes move through the inguinal canal into the scrotum, is dependent on androgens (most importantly testosterone). In rodents, androgens induce the genitofemoral nerve to release calcitonin gene-related peptide, which produces rhythmic contractions of the gubernaculum, a ligament which connects the testis to the scrotum, but a similar mechanism has not been demonstrated in humans. Maldevelopment of the gubernaculum or deficiency or insensitivity to either AMH or androgen can, therefore, prevent the testes from descending into the scrotum. Some evidence suggests an additional paracrine hormone, referred to as descendin, may be secreted by the testes.

In many infants with inguinal testes, further descent of the testes into the scrotum occurs in the first six months of life. This is attributed to the postnatal surge of gonadotropins and testosterone that normally occurs between the first and fourth months of life.

Spermatogenesis continues after birth. In the third to fifth months of life, some of the fetal spermatogonia residing along the basement membrane become type A spermatogonia. More gradually, other fetal spermatogonia become type B spermatogonia and primary spermatocytes by the fifth year after birth. Spermatogenesis arrests at this stage until puberty.

Most normal-appearing undescended testes are also normal by microscopic examination, but reduced spermatogonia can be found. The tissue in undescended testes becomes more markedly abnormal ("degenerates") in microscopic appearance between two and four years after birth. Some evidence indicates early orchiopexy reduces this degeneration.

Pathophysiology

[edit]

At least one contributing mechanism for reduced spermatogenesis in cryptorchid testes is temperature. The temperature of the testes in the scrotum is at least a few degrees cooler than in the abdomen. Animal experiments in the middle of the 20th century suggested that raising the temperature could damage fertility. Some circumstantial evidence suggests that tight underwear and other practices that raise the testicular temperature for prolonged periods can be associated with lower sperm counts. Nevertheless, research in recent decades suggests that the issue of fertility is more complex than a simple matter of temperature. Subtle or transient hormone deficiencies or other factors that lead to a lack of descent also may impair the development of spermatogenic tissue.

The inhibition of spermatogenesis by ordinary intra-abdominal temperature is so potent that continual suspension of normal testes tightly against the inguinal ring at the top of the scrotum by means of special "suspensory briefs" has been researched as a method of male contraception, and was referred to as "artificial cryptorchidism" by one report.

An additional factor contributing to infertility is the high rate of anomalies of the epididymis in boys with cryptorchidism (over 90% in some studies). Even after orchiopexy, these may also affect sperm maturation and motility at an older age.

Diagnosis

[edit]
Scrotal ultrasonography of undescended testis: (a) Normal testis in the scrotum (b) Atrophic and decreased echogenicity of the contralateral testis of the same patient seen in the inguinal region[citation needed]

The most common diagnostic dilemma in otherwise normal boys is distinguishing a retractile testis from a testis that will not descend spontaneously into the scrotum. Retractile testes are more common than truly undescended testes and do not need to be operated on. In normal males, as the cremaster muscle relaxes or contracts, the testis moves lower or higher ("retracts") in the scrotum. This cremasteric reflex is much more active in infant boys than older men. A retractile testis high in the scrotum can be difficult to distinguish from a position in the lower inguinal canal. Though various maneuvers are used to do so, such as using a cross-legged position, soaping the examiner's fingers, or examining in a warm bath, the benefit of surgery in these cases can be a matter of clinical judgment.

In the minority of cases with bilaterally nonpalpable testes, further testing to locate the testes, assess their function, and exclude additional problems is often useful. Scrotal ultrasound or magnetic resonance imaging performed and interpreted by a radiologist can often locate the testes while confirming the absence of a uterus. At ultrasound, the undescended testis usually appears small, less echogenic than the contralateral normal testis and usually located in the inguinal region.[citation needed] With color Doppler ultrasonography, the vascularity of the undescended testis is poor.[citation needed]

A karyotype can confirm or exclude forms of dysgenetic primary hypogonadism, such as Klinefelter syndrome or mixed gonadal dysgenesis. Hormone levels (especially gonadotropins and AMH) can help confirm that hormonally functional testes are worth attempting to rescue, as can stimulation with a few injections of human chorionic gonadotropin to elicit a rise in the testosterone level. Occasionally, these tests reveal an unsuspected and more complicated intersex condition.

In the even smaller minority of cryptorchid infants who have other obvious birth defects of the genitalia, further testing is crucial and has a high likelihood of detecting an intersex condition or other anatomic anomalies. Ambiguity can indicate either impaired androgen synthesis or reduced sensitivity. The presence of a uterus by pelvic ultrasound suggests either persistent Müllerian duct syndrome (AMH deficiency or insensitivity) or a severely virilized genetic female with congenital adrenal hyperplasia. An unambiguous micropenis, especially accompanied by hypoglycemia or jaundice, suggests congenital hypopituitarism.

Treatment

[edit]
Intersex topics
Intersex flag
Human rights and legal issues
Healthcare and biology
Society and culture
History and events
Rights by country
See also

The primary management of cryptorchidism is watchful waiting, due to the high likelihood of self-resolution. Where this fails, orchiopexy is effective if inguinal testes have not descended after 4–6 months. Surgery is often performed by a pediatric urologist or pediatric surgeon, but in many communities, still by a general urologist or surgeon.

Since undescended testicles do not descend after the first months of life, waiting longer only delays treatment.[17]

When the undescended testis is in the inguinal canal, hormonal therapy is sometimes attempted and very occasionally successful. The most commonly used hormone therapy is human chorionic gonadotropin (hCG). A series of hCG injections (10 injections over five weeks is common) is given, and the status of the testis/testes is reassessed at the end. Although many trials have been published, the reported success rates range widely, from roughly 5% to 50%, probably reflecting the varying criteria for distinguishing retractile testes from low inguinal testes. Hormone treatment does have the occasional incidental benefits of allowing confirmation of Leydig cell responsiveness (proven by a rise of the testosterone by the end of the injections) or inducing additional growth of a small penis (via the testosterone rise). Some surgeons have reported facilitation of surgery, perhaps by enhancing the size, vascularity, or healing of the tissue. A newer hormonal intervention used in Europe is the use of GnRH analogs such as nafarelin or buserelin; the success rates and putative mechanism of action are similar to hCG, but some surgeons have combined the two treatments and reported higher descent rates. Limited evidence suggests that germ cell count is slightly better after hormone treatment; whether this translates into better sperm counts and fertility rates at maturity has not been established. The cost of either type of hormone treatment is less than that of surgery, and the chance of complications at appropriate doses is minimal. Nevertheless, despite the potential advantages of a trial of hormonal therapy, many surgeons do not consider the success rates high enough to be worth the trouble, since the surgery itself is usually simple and uncomplicated.

In cases where the testes are identified preoperatively in the inguinal canal, orchiopexy is often performed as an outpatient and has a very low complication rate. An incision is made over the inguinal canal. The testis with accompanying cord structure and blood supply is exposed, partially separated from the surrounding tissues ("mobilized"), and brought into the scrotum. It is sutured to the scrotal tissue or enclosed in a "subdartos pouch". The associated passage back into the inguinal canal is closed to prevent reascension. In patients with intra-abdominal maldescended testis, laparoscopy is useful to see for oneself the pelvic structures, position of the testis, and decide upon surgery (single or staged procedure).

Surgery becomes more complicated if the blood supply is not ample and elastic enough to be stretched into the scrotum. In these cases, the supply may be divided, some vessels sacrificed with the expectation of adequate collateral circulation. In the worst case, the testis must be "autotransplanted" into the scrotum, with all connecting blood vessels cut and reconnected (anastomosed).

When the testis is in the abdomen, the first stage of surgery is exploration to locate it, assess its viability, and determine the safest way to maintain or establish the blood supply. Multistage surgeries, or autotransplantation and anastomosis, are more often necessary in these situations. Just as often, intra-abdominal exploration discovers that the testis is nonexistent ("vanished"), or dysplastic and not salvageable.

The principal major complication of all types of orchiopexy is a loss of the blood supply to the testis, resulting in loss of the testis due to ischemic atrophy or fibrosis.

Other animals

[edit]

Cryptorchidism is seen in all domestic animals, most commonly in stallions, boars, and canines.[18] The prevalence of this condition can vary depending on species and breed. Evidence of this condition is more likely in companion animals and swine than ruminants.[19] The cause of this condition can vary from a combination of genetics, environment, and epigenetics.[18]

Dogs

[edit]
Inguinal cryptorchidism in a Chihuahua

Cryptorchidism is common in male dogs, occurring at a rate up to 10%.[20] This condition is one of the most common congenital defects in purebred dogs (11%), with 14% reported in Siberian Huskies.[21] Although the genetics are not fully understood, it is thought to be a recessive, and probably polygenetic, trait.[22] Some have speculated that it is a sex-limited autosomal recessive trait;[23] however, it is unlikely to be simple recessive.[22] Dog testes usually descend by 10 days of age and it is considered to be cryptorchidism if they do not descend by the age of eight weeks.[24] Cryptorchidism can be either bilateral (causing sterility) or unilateral, and inguinal or abdominal (or both). Because it is an inherited trait, affected dogs should not be bred and should be castrated. The parents should be considered carriers of the defect, and a breeder should thoughtfully consider whether to breed the carrier parent or not. Littermates may be normal, carriers, or cryptorchid. Castration of the undescended teste(s) should be considered for cryptorchid dogs due to the high rate of testicular cancer, especially Sertoli cell tumors.[24] The incidence of testicular cancer is 13.6 times higher in dogs with abdominally retained testicles compared with normal dogs.[20] Testicular torsion is also more likely in retained testicles. Surgical correction is by palpation of the retained testicle and subsequent exploration of the inguinal canal or abdomen, but showing altered dogs is against AKC rules, making this correction pointless for breeding stock. Orchiopexy is an option for pet dogs that will not be used for breeding.

Commonly affected breeds include:[23]

A retained testicle with cancer removed during necropsy of a dog

Cats

[edit]

Cryptorchidism is rarer in cats than it is in dogs. In one study, 1.9% of intact male cats were cryptorchid.[25] Persians are predisposed.[26] Normally, the testicles are in the scrotum by the age of six to eight weeks. Male cats with one cryptorchid testicle may still be fertile; however, male cats with two cryptorchid testicles are most likely to be sterile.[27] Urine spraying is one indication that a cat with no observable testicles may not be neutered; other signs are the presence of enlarged jowls, thickened facial and neck skin, and spines on the penis (which usually regress within six weeks after castration).[28] Most cryptorchid cats present with an inguinal testicle.[29] Testicular tumors and testicular torsion are rare in cryptorchid cats, but castration is usually performed due to unwanted behavior such as urine spraying.

Horses

[edit]

In horses, cryptorchidism is sufficiently common that affected males (ridglings) are routinely gelded.

Rarely, cryptorchidism is due to the presence of a congenital testicular tumor such as a teratoma, which has a tendency to grow large.[30]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Cryptorchidism

View on Grokipedia
from Grokipedia
Cryptorchidism, or undescended testis, is the most prevalent congenital disorder of the male genitalia, defined by the failure of one or both testes to descend from the abdomen into the scrotum by birth. Normal testicular descent occurs during fetal development in two stages: the transabdominal stage (approximately 8-15 weeks gestation) and the inguinoscrotal stage (starting around 26 weeks gestation, usually complete by term). Most testicles are in the scrotum by birth, with spontaneous descent in many remaining cases occurring by 3-6 months of age; descent does not occur during puberty, and persistence beyond 6-12 months of age is considered abnormal, requiring evaluation. It affects approximately 2.4% to 5% of full-term male newborns at birth, with prevalence decreasing to about 1% by one year of age due to spontaneous descent in many cases. Bilateral involvement occurs in roughly 30% of cases, while unilateral cryptorchidism predominates. The condition arises from multifactorial etiologies, including gestational factors such as preterm birth, low birth weight, and intrauterine growth restriction, alongside potential genetic and environmental influences disrupting normal testicular migration during fetal development. Acquired cryptorchidism, involving postnatal ascent of previously descended testes, affects up to 2% of prepubertal boys and shares similar risk profiles. Diagnosis typically relies on physical examination, with imaging reserved for atypical presentations to locate non-palpable testes. Untreated cryptorchidism elevates risks of —particularly in bilateral cases, where impairment stems from elevated intra-abdominal temperatures hindering maturation—testicular tumors with a 4- to 6-fold increased incidence, , and torsion. Surgical intervention via , recommended between 6 and of age, aims to mitigate these complications by positioning the testis in the , though it does not fully eliminate cancer risk and may preserve potential more effectively when performed early. Hormonal therapies like hCG show and are not routinely endorsed.

Overview and Epidemiology

Definition and Classification

Cryptorchidism, also known as undescended testis, is defined as the failure of one or both testes to achieve and maintain a scrotal position, where the testis cannot be manually manipulated to the bottom of the scrotum without tension. In typical development, testes originate in the abdomen near the kidneys and descend via the inguinal canal into the scrotum, guided by the gubernaculum—a mesenchymal cord that shortens and remodels to direct migration—primarily between the 25th and 35th weeks of gestation. Although some postnatal descent occurs, cryptorchidism is diagnosed if the testis remains extrascrotal by approximately 6 months of age, as spontaneous descent thereafter is rare. Classification of cryptorchidism distinguishes between congenital and acquired forms. Congenital cryptorchidism arises from impaired prenatal descent, evident at birth or shortly thereafter, whereas acquired cryptorchidism involves testes that were scrotal postnatally but ascend later, often due to cremasteric muscle hyperactivity or low scrotal temperature thresholds. It is further categorized as unilateral, affecting one testis, or bilateral, involving both, with unilateral cases predominating. Anatomical position refines classification: abdominal (intra-abdominal, impalpable), inguinal (within the canal, often palpable), or ectopic (deviated from the normal path, such as superficial inguinal pouch or perineal sites).

Prevalence and Incidence

Cryptorchidism occurs in approximately 3% of full-term male infants at birth, with the prevalence declining to around 1% by 6 to 12 months of age as some testes descend spontaneously. In the United States, the birth prevalence stands at 3.7%, dropping to 1.1% from age 1 year through adulthood. Globally, rates at birth range from 1% to 5%, reflecting variations in study methodologies and populations, though recent prospective data from Estonia report 2.1% overall at birth and 1.1% among full-term infants. Preterm infants exhibit markedly higher rates, with prevalence estimated at 30% or greater, compared to 3% in full-term births. In China, nationwide surveillance from 2008 to 2022 indicates a prevalence of 2% to 4% in full-term newborns, with no significant temporal escalation observed over the period. Geographic and ethnic variations exist, with slightly higher prevalence among white Americans (1.90%) than black Americans (1.55%), and regional differences within Europe such as lower rates in Finland compared to Denmark. These disparities may stem partly from diagnostic criteria and ascertainment biases, including underreporting in low-resource settings where physical examinations at birth are less systematic. Overall, epidemiological data suggest relative stability in prevalence over recent decades, without consistent evidence of broad secular increases when accounting for improved diagnostics.

Risk Factors Overview

Prematurity and low birth weight represent the strongest empirically established risk factors for cryptorchidism, with prevalence rates reaching up to 30% in preterm male infants compared to 1-3% in full-term infants. Meta-analyses and large cohort studies consistently report odds ratios (OR) of 5-10 for preterm birth (<37 weeks gestation) and very low birth weight (<1500 g), reflecting a dose-dependent relationship where earlier gestation and lower weight amplify risk. Small for gestational age (SGA) status independently elevates risk, with an adjusted OR of approximately 2.0 in prospective birth cohorts, often compounding the effects of prematurity. These associations persist after controlling for confounders like maternal age and smoking, underscoring gestational and fetal growth impairments as key predisposing elements. Family history confers a moderate but heritable risk, with siblings of affected boys facing 3- to 8-fold higher odds and paternal history linked to 2- to 5-fold increases, based on nationwide cohort data and recurrence risk ratios from twin and sibling studies. Multiple births, particularly twinning, further heighten susceptibility, with ORs around 2.3-2.6 observed in large registries, likely due to shared intrauterine constraints rather than purely genetic factors, as concordance rates show limited disparity between monozygotic and dizygotic pairs. Cryptorchidism exhibits a multifactorial etiology, wherein these perinatal and familial factors interact without a single dominant cause, as evidenced by variable penetrance across populations and the absence of consistent environmental modifiers in high-quality epidemiological reviews. While associations with maternal obesity or cesarean delivery appear in some cohorts (OR ~1.5-2.0), they lack the robustness of gestational metrics and require cautious interpretation due to potential confounding by indication. Empirical data from prospective studies prioritize these quantifiable risks over speculative influences, highlighting the need for targeted screening in high-risk neonates.

Etiology

Genetic and Hormonal Causes

Cryptorchidism exhibits substantial heritability, with estimates from familial aggregation studies indicating a relative risk ratio of 10.1 for same-sex twins and 0.67 for first-degree male relatives. Twin concordance rates further support a genetic component, showing higher similarity in monozygotic versus dizygotic pairs, consistent with polygenic inheritance patterns observed in human cohorts. Specific genetic mutations implicated in testicular descent failure include those in the INSL3 gene, which encodes insulin-like factor 3 essential for gubernacular development, and its receptor RXFP2. Cumulative prevalence across studies reports INSL3 mutations in approximately 1.8% of cryptorchid cases and RXFP2 mutations in 2.9%, with higher rates (up to 4%) in persistent unilateral forms. HOXA10 mutations, involved in regulating Wolffian duct and gubernaculum formation, occur in about 11% of some patient cohorts. These findings are validated in animal models, where Insl3 or Rxfp2 knockout mice exhibit bilateral intra-abdominal testes, mirroring human phenotypes and establishing causal roles via disrupted ligand-receptor signaling. Syndromic associations underscore genetic etiology; Klinefelter syndrome (47,XXY), the most frequent chromosomal anomaly in cryptorchidism, presents in up to 1.3% of affected newborns and features undescended testes due to impaired gonadal development and hypogonadism. Hormonal deficits contribute via disrupted endocrine signaling, often genetically mediated. Reduced testosterone levels, critical for inguinoscrotal descent, correlate with androgen receptor (AR) variants and are evident in human studies of persistent cryptorchidism, where prepubertal boys show lower serum testosterone alongside diminished Leydig cell function. Anti-Müllerian hormone (AMH) deficiencies, produced by Sertoli cells, impair early transabdominal descent; mutations in AMH or its receptor (AMHR2) cause persistent Müllerian duct syndrome with associated cryptorchidism. Animal models confirm causality, as androgen receptor ablation in mice yields cryptorchidism through failed scrotal migration, independent of Insl3 pathways. Gonadotropin deficiencies, as in congenital hypogonadotropic hypogonadism, further link central hormonal axes to descent failure, with human data showing co-occurrence in syndromic cases.

Environmental and Lifestyle Factors

Studies have investigated environmental exposures as potential contributors to cryptorchidism, particularly endocrine-disrupting chemicals (EDCs) such as phthalates and pesticides, though human evidence remains inconsistent and largely associative without establishing causation. Animal models demonstrate that high-dose phthalate exposure disrupts testicular descent via anti-androgenic effects, but epidemiological data in humans show mixed results, with some cohort studies reporting modest odds ratios (ORs) of 1.2–1.5 for cryptorchidism linked to amniotic fluid phthalate metabolites, while others find no significant correlations after adjusting for confounders like birth weight. Similarly, pesticide exposures, including organochlorines, exhibit geographical clustering compatible with higher cryptorchidism rates in agricultural areas, yet prospective studies often report null or weak associations (ORs <1.5), underscoring challenges in isolating effects from multifactorial influences. Paternal lifestyle factors, such as smoking and occupational exposures, have been hypothesized to impair spermatogenesis or transmit epigenetic changes, but quantified risks are modest and debated. Paternal smoking prior to conception shows associations with elevated cryptorchidism risk in some case-control analyses (OR ≈1.3–1.8), potentially via oxidative stress on sperm DNA, though confounding by socioeconomic status and recall bias limits interpretability; larger cohorts report weaker or null links. Occupational paternal exposures to pesticides or solvents yield similar modest ORs (<2), but lack mechanistic proof in humans beyond animal extrapolations. Critically, despite documented increases in ambient EDC levels over decades, empirical data reveal no consistent temporal rise in cryptorchidism prevalence, which stabilizes at 2–4% at birth and ≈1% by age one year across multiple regions, arguing against dominant environmental causation and favoring multifactorial etiology with genetic primacy.

Maternal and Perinatal Influences

Maternal smoking during pregnancy is associated with an elevated risk of cryptorchidism in male offspring, with large cohort studies reporting adjusted hazard ratios of approximately 1.18 (95% CI: 1.12–1.24). This association persists after controlling for confounders such as gestational age and birth weight, though the causal mechanism—potentially involving nicotine's disruption of androgen signaling or gubernacular cell migration—remains under investigation in animal models and human epidemiology. Meta-analyses of observational studies confirm this link, drawing from over 30 reports including case-control and cohort designs, while smaller studies occasionally report null findings due to limited power. Advanced maternal age greater than 35 years shows inconsistent associations with cryptorchidism, with some cohort data indicating minimal differences in mean age between affected and unaffected sons, while others suggest a modest increase potentially confounded by parity or socioeconomic factors. Systematic reviews highlight mixed results across populations, attributing variability to unadjusted gestational factors rather than age per se as a direct causal driver. Assisted reproductive technologies (ART), including in vitro fertilization (IVF), correlate with higher cryptorchidism rates, likely due to elevated estrogen exposure or underlying parental infertility factors, with reviews of cohort studies showing increased odds for urogenital malformations like cryptorchidism (adjusted OR >1.5 in multiple analyses). A 2023 cohort analysis of live-born singletons further quantified slightly elevated malformation risks post-ART, emphasizing the need to distinguish procedure-specific effects from subfertility confounders. These findings stem from large registries tracking over 100,000 ART pregnancies, where cryptorchidism prevalence exceeds spontaneous conceptions by 1.5–2-fold. Perinatal obstetric factors such as breech presentation exhibit a strong unadjusted association with cryptorchidism (OR ≈3.1, 95% CI significant after plurality adjustment), observed in prospective birth cohorts where 9.4% of affected boys presented as breech versus 3.0% of controls. Cesarean delivery shows a crude OR of 1.83 (95% CI: 1.18–2.83), but this attenuates to nonsignificance upon adjustment for gestational age and birth weight, indicating it as a marker rather than independent risk. Prematurity and low birth weight confound many such perinatal links, as cryptorchidism prevalence rises exponentially below 37 weeks gestation (up to 20–30% in very preterm infants), underscoring the primacy of incomplete testicular descent due to abbreviated gestation over delivery mode alone.

Pathophysiology

Normal Testicular Descent

The process of normal testicular descent in human males unfolds in two sequential phases during gestation, ensuring the testes relocate from an intra-abdominal position to the scrotum. The transabdominal phase commences between 8 and 15 weeks of gestation, during which the testes migrate caudally from their origin near the mesonephros toward the internal inguinal ring; this involves cranial-to-caudal progression guided by differential growth and anchoring structures. The gubernaculum, a gelatinous mesenchymal ligament extending from the caudal pole of the testis to the inguinal region, plays a central role by swelling and proliferating to stabilize the testis in the low abdomen, preventing cranial displacement as the body elongates. Histological examinations reveal increased gubernacular cellularity, with mesenchymal cells exhibiting heightened mitosis and extracellular matrix deposition, reflecting active cytoskeletal remodeling and tissue expansion. This initial phase is hormonally driven primarily by insulin-like factor 3 (INSL3), produced by fetal Leydig cells starting around 9 weeks, which binds to the relaxin-family peptide receptor 2 (RXFP2) on gubernacular cells to induce proliferation independent of androgens. Insl3 knockout models in mice demonstrate failure of gubernacular enlargement and halted transabdominal migration, underscoring the hormone's necessity for anchoring without propulsion. Anti-Müllerian hormone (AMH) from Sertoli cells may provide supplementary inhibition of cranial ligaments, though its role remains adjunctive based on in vitro proliferation assays. The subsequent inguinoscrotal phase, occurring from 25 to 35 weeks of , entails the testis passing through the into the via processus vaginalis evagination, completing by term in 97% of cases. signaling dominates here, with testosterone from Leydig cells and its metabolite () directly on receptors in the to promote caudal outgrowth and remodeling for propulsion, while also stimulating the to release (), which provides neurotropic guidance for directional migration. Gubernacular shifts to include increased , muscle-like differentiation in the cremasteric component, and regression of the bulbous tip, facilitating scrotal positioning. Most testicles are in the scrotum by birth, with spontaneous descent occurring in many remaining cases by 3-6 months of age. Descent after 6 months is uncommon and rare beyond 12 months; if testicles are not descended by 6-12 months, it is considered abnormal (cryptorchidism) and requires evaluation. Testicular descent does not occur during puberty (typically ages 9-14), when the testicles enlarge and mature but remain in their pre-pubertal position if previously undescended. In some cases of retractile testicles (a benign variant where the testicles can temporarily retract into the inguinal region due to cremasteric reflex activity), they may stabilize permanently in the scrotum during puberty due to testicular growth and reduced reflex activity. These molecular and cellular events exhibit evolutionary conservation, as rodent and marsupial models replicate INSL3/RXFP2-mediated transabdominal anchoring and androgen/CGRP-dependent inguinoscrotal traversal, with gubernacular dynamics preserved across therian mammals despite variations in scrotal timing.

Mechanisms of Descent Failure

The failure of testicular descent in cryptorchidism arises from disruptions in the gubernaculum's biomechanical role during the inguinoscrotal phase, where insufficient swelling or impaired regression prevents the testis from traversing the inguinal canal into the scrotum. Histological examinations reveal gubernacular defects, including reduced extracellular matrix remodeling and failure of collagen fiber alignment, as observed in animal models where insulin-like factor 3 (INSL3) knockout leads to absent gubernacular enlargement and persistent intra-abdominal positioning. In human cases, analogous deficiencies in INSL3 receptor (RXFP2) signaling impair cAMP-mediated gubernacular outgrowth, confirming a primary mechanical shortfall independent of secondary influences. Hormonal insufficiencies, particularly androgen signaling defects, exacerbate descent failure by hindering gubernacular androgen-dependent regression and cremaster muscle differentiation. Studies of androgen receptor expression in bilateral cryptorchid boys demonstrate reduced binding affinity and nuclear translocation in gubernacular tissues, mirroring partial androgen insensitivity where testes remain abdominal despite normal testosterone levels. Cremaster muscle anomalies, such as histological evidence of myofiber disorganization and excessive collagen deposition, further contribute by promoting abnormal retraction or fixation, with biopsies showing thickened muscle layers in undescended specimens compared to descended controls. These primary mechanical and hormonal failures result in persistent abdominal or inguinal retention, exposing germ cells to elevated intra-abdominal temperatures (approximately 34–35°C versus scrotal 33°C), which induce biophysical stress via heat shock proteins and caspase activation, leading to apoptosis. Biopsy data from cryptorchid testes indicate progressive germ cell loss, with gonocyte counts dropping by 80–90% within the first postnatal year and near-total Ad spermatogonia absence by age 2, as quantified in serial histological analyses correlating temperature duration with Sertoli cell-only patterns. Multifactorial causal models integrate these elements, positing that core disruptions in gubernacular mechanotransduction and androgen/INSL3 hormonal cascades predominate, with downstream germ cell atrophy as a direct biophysical consequence rather than an initiating factor; empirical rodent knockouts and human receptor variants support this hierarchy over diffuse environmental perturbations.

Clinical Presentation

Signs and Symptoms

Cryptorchidism typically presents with the absence of one or both testes in the scrotum, often noted at birth or during routine pediatric examinations. In unilateral cases, which comprise approximately 90% of instances, scrotal asymmetry is evident, with the affected side appearing underdeveloped or empty compared to the contralateral normal scrotum. Bilateral involvement occurs in about 10% of cases. Of cryptorchid testes, roughly 70% are palpable, typically located in the inguinal canal or upper scrotum, presenting as a firm, non-tender mass that cannot be manipulated into the scrotum. The remaining 30% are nonpalpable, meaning no testicular structure can be identified on physical examination, which may indicate an intra-abdominal position, atrophy, or agenesis. In approximately 80% of affected newborns, the ipsilateral scrotum is empty at birth, while in the other cases, a testis may be palpable in the inguinal region. Distinguishing true cryptorchidism from retractile testes, which can be manually brought into the scrotum but ascend due to cremasteric reflex, is age-dependent; retractile testes constitute a notable portion of initial presentations in infancy but require observation as up to 32% may later ascend and mimic persistent undescended states. An associated or processus vaginalis is frequently observed, manifesting as a reducible bulge in the , particularly during or straining, due to the shared embryologic pathway of testicular descent. Acute symptoms are uncommon but can include sudden or , swelling, , or if torsion of the undescended testis occurs, representing a .

Associated Conditions and Complications

Cryptorchidism is associated with various concurrent congenital anomalies, particularly within the genitourinary tract. Hypospadias, a malformation of the urethral opening, co-occurs with undescended testes in approximately 5-10% of cases, reflecting shared disruptions in embryologic development of the external genitalia. Urinary tract anomalies, such as renal agenesis or vesicoureteral reflux, overlap with cryptorchidism in 10-12% of affected individuals, with higher rates observed in bilateral cases; excretory urography in one series revealed abnormalities in 12% of 205 patients evaluated. These associations underscore the need for comprehensive genitourinary evaluation in diagnosed cases. Systemic conditions and syndromes also link to cryptorchidism, though less commonly. Prader-Willi syndrome, characterized by hypotonia and developmental delays, features undescended testes in up to 80% of affected males due to hypothalamic-pituitary dysfunction. Chromosomal abnormalities, including Klinefelter syndrome (47,XXY), are identified in about 3% of boys with cryptorchidism, often as part of syndromic presentations involving hypogonadism. Immediate complications include inguinal hernia and testicular torsion. Undescended testes are linked to inguinal hernia via a persistent processus vaginalis, with clinical hernias manifesting in 10-30% of untreated cases, though patent processes occur in up to 90%. Testicular torsion, a surgical emergency involving vascular compromise, carries an elevated risk in ectopic testes—estimated at 4-10 times higher than in descended ones—due to anomalous fixation and mobility, though absolute incidence remains low at under 1%.

Diagnosis

Physical Examination

The diagnosis of cryptorchidism relies primarily on physical examination of the genitalia, performed in a warm room with the patient relaxed to reduce cremasteric reflex activity and distinguish retractile testes from true undescended ones. The examiner warms their hands and positions the infant supine, gently palpating bilaterally from the abdomen downward along the inguinal canal toward the scrotum in a sweeping motion to locate or mobilize the testis. If the testis can be manipulated into the scrotum and remains in a dependent position, it is classified as retractile, often due to a hyperactive cremasteric muscle; failure to achieve this indicates true cryptorchidism. Bilateral assessment is essential, as cryptorchidism can affect one or both testes, with the right side more commonly involved in unilateral cases. In experienced hands, approximately 70% of undescended testes are palpable, typically located in the superficial inguinal pouch, while the remainder are nonpalpable. Techniques such as having the child adopt a squatting or cross-legged position may further aid in relaxing the reflex and confirming testicular position. According to American Urological Association (AUA) guidelines, physical examination should be conducted at birth and repeated around 6 months of age to confirm persistence, as spontaneous descent occurs in many preterm cases by this time. Palpation demonstrates high reliability for palpable testes but requires expertise to avoid misclassification of retractile or ascending testes.

Imaging and Laboratory Tests

Diagnostic imaging is not routinely recommended for cryptorchidism evaluation, as physical examination adequately identifies palpable testes, and for nonpalpable cases, no radiological test achieves 100% accuracy in confirming testicular absence or location, making surgical exploration preferable. Ultrasound serves as an initial imaging modality in some protocols for nonpalpable testes, offering non-invasive assessment, but its sensitivity ranges from 45% to 84% and specificity from 78% to 100% across studies, with meta-analyses indicating it frequently fails to localize intra-abdominal testes reliably. For suspected abdominal testes, magnetic resonance imaging (MRI) provides superior sensitivity (up to 100%) and specificity (89-100%) compared to ultrasound or computed tomography (CT), though CT involves ionizing radiation risks and both modalities require sedation in young children, limiting their routine utility. Diagnostic laparoscopy remains the gold standard for nonpalpable testes, allowing direct visualization, biopsy if needed, and therapeutic intervention in a single procedure, with high accuracy in distinguishing anorchia from intra-abdominal cryptorchidism. Laboratory tests assess testicular viability and presence, particularly in bilateral nonpalpable cases to guide management. Basal anti-Müllerian hormone (AMH) levels below detectable thresholds (e.g., <0.2 ng/mL in prepubertal boys) strongly indicate anorchia with high specificity, outperforming historical hCG stimulation tests. The hCG stimulation test involves administering 1500-5000 IU hCG intramuscularly over 1-5 days, measuring serum testosterone response; a post-stimulation increase exceeding 100-400 ng/dL or to adult levels confirms functional Leydig cells, though false negatives occur in prepubertal boys due to low baseline responsiveness. Evidence highlights over-reliance on imaging, as routine ultrasound prior to referral does not alter surgical plans, incurs costs of $500-2000 per scan, and delays timely orchiopexy by weeks to months, potentially worsening outcomes without diagnostic benefit. Guidelines from the American Urological Association and others explicitly advise against pre-referral imaging to optimize cost-effectiveness and expedite care.

Treatment

Indications and Timing

Surgical intervention is indicated for congenital cryptorchidism that persists beyond the early postnatal period, as spontaneous descent becomes increasingly unlikely after 3 months of age, occurring in 35-43% of cases longitudinally observed in newborns, primarily prior to this timeframe. The American Urological Association (AUA) guidelines recommend referral for surgical repair by 6 months corrected for gestational age if the testis remains undescended, with orchiopexy performed between 6 and 18 months to optimize testicular health outcomes based on histological evidence of germ cell deterioration with prolonged maldescent. Similarly, the European Association of Urology (EUA) endorses orchidopexy between 6 and 12 months for persistent cases, reflecting consensus on minimizing risks through early correction. Indications do not differ fundamentally by laterality, though bilateral cryptorchidism warrants prompt evaluation due to higher associated risks of endocrine abnormalities; both unilateral and bilateral persistent cases require intervention if undescended by 6 months. For palpable testes, orchiopexy is the standard approach regardless of unilaterality, while non-palpable testes necessitate surgical exploration—via laparoscopy for unilateral cases or open methods where appropriate—to confirm presence and location, with timing aligned to the 6-18 month window to avoid diagnostic delays. Evidence supporting extended watchful waiting beyond 6 months is limited, with spontaneous descent rates dropping to under 7% in infants reexamined at 1 year or older, underscoring the rationale for guideline-directed timelines over prolonged observation. Acquired cryptorchidism in older children may allow for initial monitoring if retractile features are present, but congenital persistence mandates treatment to prevent progressive histological changes.

Surgical Options

The primary surgical intervention for cryptorchidism is orchidopexy, which involves mobilizing the undescended testis and fixing it in the scrotum to promote normal development and reduce risks such as malignancy. For palpable testes typically located in the inguinal region, an open inguinal orchidopexy is performed, achieving success rates of approximately 89-96% in positioning the testis without ascent or atrophy. Abdominal approaches are reserved for intra-abdominal testes, often via laparoscopy, which allows for both diagnosis and treatment in a single procedure, with reported success rates of 81-100% for vessel-preserving techniques. For high intra-abdominal testes where the spermatic vessels are too short to reach the scrotum without tension, the Fowler-Stephens procedure is indicated, involving intentional division of the spermatic artery to rely on collateral circulation from the vasal and cremasteric vessels. Single-stage Fowler-Stephens orchidopexy yields success rates of 78-85%, while two-stage variants—where vessel division precedes orchidopexy by 3-6 months to allow collateral development—improve outcomes to 86-90%, with testicular atrophy rates reduced to around 10-11% compared to 17% in single-stage. Overall complication rates for orchidopexy procedures remain low at under 5%, encompassing minor issues like wound infection or hematoma, though ascent and atrophy risks are higher in abdominal cases. Laparoscopic techniques have advanced the management of non-palpable testes, enabling minimally invasive single-stage vessel-preserving orchidopexy with success rates up to 100% in select pediatric cohorts, minimizing the need for vessel division. These approaches reduce operative time and recovery compared to open methods, with two-stage laparoscopic Fowler-Stephens preferred for very high testes to optimize vascular preservation. The COVID-19 pandemic exacerbated disparities in surgical access, with reduced progression to timely orchidopexy—particularly among Hispanic and African American males—leading to delays beyond the recommended 6-18 months, potentially worsening outcomes due to prolonged testicular malposition.

Medical and Observational Management

Hormonal therapies, including human chorionic gonadotropin (hCG) and luteinizing hormone-releasing hormone (LHRH, also known as GnRH analogs), aim to induce testicular descent by stimulating androgen production or gonadotropin release. hCG, administered via intramuscular injections at doses escalating with age (e.g., 250-1000 IU twice weekly for 5 weeks), yields descent rates of 6-21% in randomized controlled trials. A meta-analysis of hCG treatment found it no more effective than placebo for descent. LHRH, typically delivered as a nasal spray (e.g., buserelin), reports controlled study success rates of 6-38%, with combined hCG-LHRH approaches reaching up to 65% in some uncontrolled data but lacking robust long-term validation. Overall efficacy remains limited, often below 20%. These treatments show no proven fertility benefits, with meta-analyses and guidelines citing insufficient evidence of improved spermatogenesis or germ cell preservation; some studies indicate potential harm to germ cell counts from hormonal exposure. The American Urological Association (AUA) explicitly recommends against routine hormonal therapy due to low response rates, absence of durable outcomes, and risks such as precocious puberty markers (e.g., penile enlargement, pubic hair) or, at high doses, epiphyseal closure. Historical use has declined sharply since the 1990s, driven by accumulating trial data demonstrating marginal gains outweighed by surgical alternatives' superior reliability. Observational management entails periodic monitoring without intervention, reserved for low-risk scenarios like unilateral palpable testes near the scrotal border or initially misclassified retractile cases, where spontaneous descent remains plausible up to 6 months of age. Criteria include serial physical exams every 3-6 months to track position, volume, and viability, prioritizing cases without bilateral involvement or intra-abdominal location. Descent rates drop markedly after 6 months (to <1% annually), prompting AUA guidance for evaluation by 6 months and intervention by 12-18 months to mitigate fertility impairment and oncogenic risks if persistence occurs. Prolonged observation beyond infancy is not endorsed for confirmed cryptorchidism.

Prognosis

Fertility Outcomes

Men with cryptorchidism experience diminished fertility potential, characterized by reduced sperm concentration, motility, and overall semen quality in adulthood. Longitudinal follow-up studies report infertility rates of 10-32% in unilateral cases, reflecting mild to moderate impairment, compared to 50-59% in bilateral cases where spermatogenic failure is more pronounced. Bilateral cryptorchidism correlates with worse parameters and higher reliance on during assisted , as evidenced by comparative analyses of orchidopexy patients. Paternity rates in treated unilateral cases approach near-normal levels (around 90%), whereas bilateral involvement elevates and extends time to conception. Surgical timing critically influences outcomes through germ cell preservation; orchidopexy performed before 12 months mitigates postnatal germ cell loss observed after 6 months, yielding higher adult sperm counts (up to 76% normal in bilateral cases if operated before 4 years). Delayed intervention beyond infancy accelerates tubular atrophy and depletes spermatogonia, independent of age up to 12 years in unilateral disease but with persistent deficits if germ cells are absent at biopsy. Epigenetic dysregulation, including altered DNA methylation and histone modifications in cryptorchid testes, underlies defective germ cell differentiation and contributes to infertility pathogenesis, as detailed in 2023 analyses linking these changes to impaired spermatogenesis.

Cancer Risk

Cryptorchidism confers a 3- to 10-fold increased relative risk of testicular germ cell tumors compared to the general population, with seminomas comprising the predominant histology in affected testes. Population-based studies, including cohort analyses from registries, indicate that 5-10% of all testicular cancer cases occur in men with a history of cryptorchidism, despite its prevalence of approximately 1% at birth. The absolute lifetime risk of malignancy in untreated cryptorchid testes remains low, estimated at 0.5-1%, though this varies by testicular position. Intra-abdominal cryptorchid testes exhibit the highest malignancy risk, with relative risks up to 40 times greater than scrotal testes and approximately four times higher than inguinal positions, based on histopathological and epidemiological data. Persistently undescended abdominal testes show a particular predisposition to seminoma development, accounting for up to 74% of tumors in such cases per tumor registry reviews. Orchiopexy performed in early childhood reduces but does not eliminate the elevated risk, with meta-analyses reporting a persistent 2- to 4-fold increase in testicular cancer incidence post-surgery compared to controls. Delays in orchiopexy beyond puberty are associated with odds ratios approaching 6 for malignancy, underscoring the benefit of timely intervention while highlighting inherent testicular vulnerabilities. Long-term surveillance, including regular self-examination and periodic ultrasonography for retained or ectopic testes, is recommended to detect rare events early, though routine screening in all corrected cases lacks strong evidentiary support due to the overall low incidence.

Long-Term Health Impacts

Individuals with untreated or late-treated cryptorchidism face an elevated risk of testicular torsion, with studies indicating up to a 10-fold increase compared to those with descended testes. This complication arises due to the abnormal position of the undescended testis, which predisposes it to twisting of the spermatic cord, potentially leading to ischemia and necrosis if not addressed emergently. Inguinal hernias are also more prevalent in this population, often co-occurring with cryptorchidism due to shared anatomical vulnerabilities in the inguinal canal. Testicular hypotrophy, marked by persistent reduction in testicular volume and impaired pubertal growth, represents a common long-term morphological , even following . Longitudinal observations show that cryptorchid testes exhibit poorer compensatory growth compared to contralateral descended testes, contributing to and potential functional deficits independent of production. Endocrine disruptions, including hypogonadism characterized by diminished testosterone and other hormone output, have been documented in adult cohorts with cryptorchidism history, linked to progressive Leydig cell impairment. Such alterations may manifest as subtle deficiencies in androgen levels, influencing metabolic and skeletal health over time, though overt clinical hypogonadism remains infrequent with early intervention. Psychological sequelae can include self-image disturbances and reduced self-esteem, exacerbated by visible scrotal asymmetry or delayed treatment, particularly in adolescents navigating body image concerns. These effects are more pronounced in unsupportive familial or social contexts, potentially impacting interpersonal relationships and mental well-being, though empirical data on prevalence vary. Despite these risks, cryptorchidism carries negligible direct mortality, with quality-of-life impairments primarily stemming from cumulative physical and emotional burdens rather than life-threatening events.

Controversies and Debates

Genetic vs. Environmental Causation

Twin and family studies demonstrate a substantial genetic contribution to cryptorchidism, with concordance rates in monozygotic twins exceeding those in dizygotic twins, indicating heritability estimates of approximately 40-60%. Familial aggregation further supports this, as first-degree relatives of affected individuals exhibit recurrence risk ratios of 3-6, far higher than the general population prevalence of 1-3%. Specific genetic variants, including mutations in the INSL3 and RXFP2 genes critical for testicular descent signaling, have been identified in familial and sporadic cases, underscoring monogenic influences in subsets of patients. Recent genomic investigations reinforce innate etiologies, with genome-wide association studies (GWAS) identifying loci such as HMGA2 variants linked to cryptorchidism risk, though primarily validated in canine models with implications for human parallels. Transcriptome analyses of undescended testes reveal massive alterations in gene expression profiles, including hundreds of differentially expressed genes unrelated to germinal DNA variants, pointing to primary developmental dysregulation rather than secondary environmental insults. These findings, from 2023-2025 studies, highlight pathways involving hormone signaling and gubernaculum development as innately disrupted, favoring genetic and hormonal primacy in multifactorial models. Environmental hypotheses, particularly prenatal exposure to endocrine-disrupting chemicals (EDCs) like phthalates or pesticides, posit interference with androgen signaling, yet evidence remains associative without establishing causation. Epidemiological reviews link maternal EDC exposure to elevated risk, but these correlations are confounded by stronger predictors like low birth weight and prematurity, and lack mechanistic validation from randomized or experimental designs feasible only in animals. Overemphasis on EDCs in some academic narratives may reflect institutional biases toward environmental determinism, despite sparse direct proof in humans and inconsistent replication across cohorts. Current consensus favors multifactorial causation dominated by genetic predispositions interacting with endogenous hormonal factors, where environmental influences, if present, act as modifiers rather than primary drivers absent robust causal data. This framework aligns with empirical genetic evidence over speculative chemical advocacy, emphasizing testable genomic insights for future risk stratification.

Treatment Efficacy and Guidelines

The efficacy of surgical intervention for cryptorchidism, primarily orchidopexy, centers on mitigating risks of infertility and malignancy, though randomized controlled trials (RCTs) indicate only modest fertility improvements from early versus delayed procedures. A 2025 systematic review and meta-analysis found that early orchidopexy (before 18 months) was associated with greater testicular volume and potentially better fertility outcomes compared to delayed surgery, but atrophy rates did not differ significantly, and data imprecision limits definitive conclusions on fertility gains. Observational studies support faster testicular growth with surgery before 12 months, yet high-quality RCTs remain sparse, highlighting evidence gaps in causal links to adult fertility preservation. Current guidelines from the American Urological Association (AUA), updated in 2025, recommend referral for surgical evaluation by 6 months of age (corrected for gestational age) if no spontaneous descent occurs, with orchidopexy performed within the next 12 months to optimize outcomes. This evolution from prior emphases on 18 months maximum reflects accumulating evidence of poorer testicular growth when surgery is delayed beyond early infancy, though benefits plateau after this window without clear additional gains in reducing malignancy risk. Providers should prioritize palpable testes for inguinal approaches and non-palpable for laparoscopic evaluation, avoiding routine hormonal therapy due to its limited long-term efficacy. Hormonal treatments, such as human chorionic gonadotropin (hCG) or luteinizing hormone-releasing hormone (LHRH), demonstrate low descent rates (around 20-30% for LHRH in meta-analyses) and no sustained fertility or malignancy risk reduction, rendering them ineffective for routine use per AUA guidance. A meta-analysis of hCG trials confirmed equivalence to placebo, while LHRH shows marginal short-term descent but lacks evidence for histological or functional testicular improvements. Orchiectomy is indicated for non-viable, dysgenetic, or atrophic testes identified intraoperatively, particularly intra-abdominal ones lacking functional tissue (e.g., absent anti-Müllerian hormone production), to eliminate malignancy risk without preserving non-contributory gonads. This approach contrasts with orchiopexy for viable testes, balancing oncologic prevention against potential endocrine contributions. Access disparities exacerbate treatment delays, with racial and ethnic minorities undergoing orchiopexy at older ages (e.g., Black and Hispanic children averaging 2-3 months later than White peers), correlating with socioeconomic factors and referral patterns that worsen fertility prognosis. Studies attribute these gaps to uneven primary care screening and specialist access, underscoring the need for targeted interventions to align real-world practice with guidelines.

Cryptorchidism in Non-Human Animals

Prevalence in Domestic Species

Cryptorchidism exhibits varying prevalence across domestic species, primarily influenced by genetic predispositions amplified through selective breeding in purebred lines, which contrasts with less intensive selection pressures in wild or less domesticated populations. In dogs, reported incidence ranges from 1.2% to 12.9%, with breed-specific variations showing higher rates in small breeds such as Chihuahuas, Pomeranians, Yorkshire Terriers, and Toy Poodles. Heritability studies confirm a genetic basis, with estimates of 0.23 in breeds like Boxers and elevated risk in purebreds due to inbreeding. In cats, is generally lower, ranging from 0.37% to 1.7% overall, though pedigreed cats show rates up to 6.2%, significantly higher than in non-pedigreed populations (1.3%). Breeds like Persians demonstrate overrepresentation, linked to hereditary factors. For horses, prevalence differs markedly by breed, with reports of 2.6% in Arabian herds and up to 14.2% in Friesians; higher incidences occur in Quarter Horses, Saddlebreds, Percherons, and ponies due to inherited traits under artificial selection. These rates underscore how domestication and breed standards elevate cryptorchidism compared to unselected equine populations, where natural selection may mitigate incomplete descent.

Veterinary Management

In veterinary practice, cryptorchidism in domestic species like dogs, cats, horses, and pigs is managed primarily through surgical castration to remove retained testes, preventing hereditary transmission and reducing the risk of testicular tumors, which occur at rates up to 13 times higher in undescended gonads compared to descended ones in dogs. This intervention is recommended for all affected companion animals, as orchiopexy fails to reliably mitigate neoplastic risks or enhance fertility and is thus not advised outside experimental contexts. For breeding animals, unilateral cases in species such as horses may warrant fertility assessment, but bilateral cryptorchidism typically disqualifies individuals from reproduction due to infertility, with surgical removal still preferred to avert health complications. Cryptorchid neutering procedures achieve success rates of over 95% for complete excision when performed by skilled surgeons, though abdominal testicles necessitate laparotomy or laparoscopy, increasing operative time and complication risks like hemorrhage by 2-5 fold relative to routine orchiectomy. Breeders mitigate incidence through selective screening, avoiding mating of affected sires, as cryptorchidism exhibits heritability estimates of 0.2-0.6 in canine populations. Advances in genomic research support breed-specific risk profiling, with genome-wide association studies identifying susceptibility loci on canine chromosomes 9, 15, and 32, enabling preliminary genetic counseling programs in high-prevalence breeds like Yorkshire Terriers and Pomeranians. Economic burdens include elevated surgical fees—often $500-2000 USD more than standard neutering—and productivity losses in livestock, where cryptorchid rams or boars yield semen production drops of up to 50%, reducing breeder income by thousands per affected animal annually. In swine, hyperprolific lines exacerbate losses through higher cryptorchid rates, prompting culling protocols to preserve herd fertility.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK470270/
  2. https://www.ncbi.nlm.nih.gov/books/NBK557763/
  3. https://www.auanet.org/guidelines-and-quality/guidelines/cryptorchidism-guideline
  4. https://journals.sagepub.com/doi/10.4137/CMRH.S25056
  5. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1343887/full
  6. https://academic.oup.com/humupd/article/14/1/49/823056
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC3602796/
  8. https://www.auajournals.org/doi/10.1016/j.juro.2014.05.005
  9. https://www.pedsurglibrary.com/apsa/view/Pediatric-Surgery-NaT/829144/1/Cryptorchidism
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC10023762/
  11. https://emedicine.medscape.com/article/438378-overview
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC11021654/
  13. https://www.merckmanuals.com/professional/pediatrics/congenital-renal-and-genitourinary-anomalies/cryptorchidism
  14. https://onlinelibrary.wiley.com/doi/10.1111/andr.13686
  15. https://www.researchgate.net/publication/11947804_Trends_in_the_incidence_of_cryptorchidism_and_hypospadias_and_methodological_limitations_of_registry-based_data
  16. https://pmc.ncbi.nlm.nih.gov/articles/PMC11194432/
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC2516600/
  18. https://academic.oup.com/aje/article/167/12/1453/89082
  19. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0003051
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC5815831/
  21. https://onlinelibrary.wiley.com/doi/full/10.1002/j.1939-4640.2003.tb02654.x
  22. https://www.sciencedirect.com/science/article/pii/S0015028208039393
  23. https://academic.oup.com/edrv/article/29/5/560/2355018
  24. https://www.sciencedirect.com/science/article/pii/S1521690X22000069
  25. https://onlinelibrary.wiley.com/doi/10.1111/and.12592
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC3327355/
  27. https://jamanetwork.com/journals/jama/fullarticle/182919
  28. https://pubmed.ncbi.nlm.nih.gov/19017913/
  29. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1347435/full
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC10944898/
  31. https://onlinelibrary.wiley.com/doi/10.1111/apm.13247
  32. https://onlinelibrary.wiley.com/doi/10.1111/iju.14600
  33. https://pubmed.ncbi.nlm.nih.gov/25384265/
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC1469503/
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC1247623/
  36. https://www.auajournals.org/doi/10.1097/01.ju.0000095793.04232.d8
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC9329573/
  38. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0119006
  39. https://www.researchgate.net/publication/277580735_Maternal_Gestational_Smoking_Diabetes_Alcohol_Drinking_Pre-Pregnancy_Obesity_and_the_Risk_of_Cryptorchidism_A_Systematic_Review_and_Meta-Analysis_of_Observational_Studies
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC10816234/
  41. https://www.fertstert.org/article/S0015-0282%2823%2900684-2/fulltext
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC4889701/
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC3126055/
  44. https://anatomypubs.onlinelibrary.wiley.com/doi/full/10.1002/ar.21393
  45. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.868313/full
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC3089031/
  47. https://journals.sagepub.com/doi/10.1177/1756287209105266
  48. https://academic.oup.com/ejendo/article/159/Supplement_1/S75/6676028
  49. https://www.ncbi.nlm.nih.gov/books/NBK279106/
  50. https://my.clevelandclinic.org/health/diseases/16601-retractile-testicle
  51. https://www.mayoclinic.org/diseases-conditions/retractile-testicle/symptoms-causes/syc-20377197
  52. https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2024.1353598/full
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC12133111/
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC9799001/
  55. https://www.auajournals.org/doi/10.1016/j.juro.2006.06.063
  56. https://pubmed.ncbi.nlm.nih.gov/2901218/
  57. https://jamanetwork.com/journals/jamapediatrics/fullarticle/514214
  58. https://pubmed.ncbi.nlm.nih.gov/17489493/
  59. https://www.sciencedirect.com/science/article/abs/pii/S0022346817302543
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC10792029/
  61. https://academic.oup.com/humrep/article/17/2/383/568957
  62. https://academic.oup.com/edrv/article/34/5/725/2354701
  63. https://www.omim.org/entry/219050
  64. https://bestpractice.bmj.com/topics/en-us/741
  65. https://emedicine.medscape.com/article/1017420-clinical
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC9441697/
  67. https://www.health.harvard.edu/a_to_z/undescended-testicle-a-to-z
  68. https://www.sciencedirect.com/science/article/pii/S0022534717536228
  69. https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2020.575741/full
  70. https://pmc.ncbi.nlm.nih.gov/articles/PMC5471079/
  71. https://www.aafp.org/pubs/afp/collections/choosing-wisely/498.html
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC3010084/
  73. https://tau.amegroups.org/article/view/5174/html
  74. https://pubmed.ncbi.nlm.nih.gov/8535728/
  75. https://www.sciencedirect.com/science/article/abs/pii/S1530891X20407402
  76. https://publications.aap.org/pediatrics/article/127/1/119/30073/Diagnostic-Performance-of-Ultrasound-in
  77. https://onlinelibrary.wiley.com/doi/10.1111/jpc.16689
  78. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1327957/full
  79. https://pubmed.ncbi.nlm.nih.gov/14713841/
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC10940471/
  81. https://emedicine.medscape.com/article/438378-treatment
  82. https://www.mdpi.com/2077-0383/13/7/2045
  83. https://pubmed.ncbi.nlm.nih.gov/30408514/
  84. https://pubmed.ncbi.nlm.nih.gov/39079708/
  85. https://www.sciencedirect.com/science/article/abs/pii/S1477513124000883
  86. https://www.jpurol.com/article/S1477-5131%2824%2900088-3/pdf
  87. https://pubmed.ncbi.nlm.nih.gov/27050251/
  88. https://pubmed.ncbi.nlm.nih.gov/24857650/
  89. https://pmc.ncbi.nlm.nih.gov/articles/PMC4074661/
  90. https://wjmh.org/DOIx.php?id=10.5534/wjmh.210198
  91. https://www.mdpi.com/2073-4425/12/12/1894
  92. https://www.eshre.eu/-/media/sitecore-files/SIGs/Surgery/Treviso-2010/Amer.pdf
  93. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1294884/full
  94. https://onlinelibrary.wiley.com/doi/full/10.1111/andr.12964
  95. https://tau.amegroups.org/article/view/5210/html
  96. https://academic.oup.com/jcem/article/97/12/4358/2536382
  97. https://pmc.ncbi.nlm.nih.gov/articles/PMC10512650/
  98. https://www.sciencedirect.com/science/article/pii/S1930043322009025
  99. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2012.00182/full
  100. https://www.nejm.org/doi/full/10.1056/NEJMoa067588
  101. https://www.hopkinsmedicine.org/health/conditions-and-diseases/testicular-cancer/testicular-cancer-risk-factors
  102. https://pmc.ncbi.nlm.nih.gov/articles/PMC3008294/
  103. https://med-fom-urlgsci.sites.olt.ubc.ca/files/2007/06/elder_-_cryptorchidism1.pdf
  104. https://pubmed.ncbi.nlm.nih.gov/36988678/
  105. https://www.sciencedirect.com/science/article/abs/pii/S1078143908000045
  106. https://pmc.ncbi.nlm.nih.gov/articles/PMC4310261/
  107. https://www.sciencedirect.com/science/article/pii/S2214388216300388
  108. https://www.aafp.org/pubs/afp/issues/2000/1101/p2037.html
  109. https://academic.oup.com/jcem/article/101/6/2570/2804860
  110. https://pmc.ncbi.nlm.nih.gov/articles/PMC6974459/
  111. https://pubmed.ncbi.nlm.nih.gov/19022430/
  112. https://jmg.bmj.com/content/56/11/727
  113. https://pmc.ncbi.nlm.nih.gov/articles/PMC11841234/
  114. https://pmc.ncbi.nlm.nih.gov/articles/PMC10873591/
  115. https://www.nature.com/articles/s41598-025-90471-9
  116. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1271724/full
  117. https://www.sciencedirect.com/science/article/pii/S0303720711006782
  118. https://pubmed.ncbi.nlm.nih.gov/27642851/
  119. https://pubmed.ncbi.nlm.nih.gov/19550382/
  120. https://omim.org/entry/219050
  121. https://pmc.ncbi.nlm.nih.gov/articles/PMC5952379/
  122. https://www.researchgate.net/publication/385157514_Timing_of_Orchidopexy_Efficacy_and_Safety_Outcomes_in_Patients_with_Cryptorchidism_Systematic_Review_and_Meta-Analysis
  123. https://www.sciencedirect.com/science/article/pii/S2949711625000140
  124. https://www.auanet.org/documents/education/clinical-guidance/Cryptorchidism.pdf
  125. https://pubmed.ncbi.nlm.nih.gov/7673426/
  126. https://www.ncbi.nlm.nih.gov/books/NBK560904/
  127. https://pmc.ncbi.nlm.nih.gov/articles/PMC9771941/
  128. https://www.jpurol.com/article/S1477-5131%2822%2900368-0/abstract
  129. https://www.sciencedirect.com/science/article/abs/pii/S1477513125001275
  130. https://avmajournals.avma.org/view/journals/javma/263/1/javma.24.04.0257.xml
  131. https://www.ivis.org/library/recent-advances-small-animal-reproduction/canine-and-feline-cryptorchidism
  132. https://pmc.ncbi.nlm.nih.gov/articles/PMC9135263/
  133. https://www.vetlexicon.com/canis/reproduction/articles/testicle-cryptorchidism/
  134. https://www.vin.com/apputil/content/defaultadv1.aspx?pId=11165&meta=generic&catId=29800&id=3848679&ind=34&objTypeID=17
  135. https://avmajournals.avma.org/view/journals/javma/200/8/javma.1992.200.08.1128.pdf
  136. https://clinicaltheriogenology.net/index.php/CT/article/view/9648/15816
  137. https://www.sciencedirect.com/science/article/abs/pii/S187114131630138X
  138. https://www.acvs.org/large-animal/cryptorchidism-undescended-testicles-in-horses/
  139. https://www.petmd.com/horse/conditions/reproductive/c_hr_cryptorchidism
  140. https://veterinarypartner.vin.com/default.aspx?pid=19239&id=4952745
  141. https://vscsarasota.com/wp-content/uploads/2023/02/Cryptorchidism-in-Dogs-and-Cats.pdf
  142. https://www.mdpi.com/2306-7381/11/6/243
  143. https://www.cliniciansbrief.com/article/cryptorchid-neuter
  144. https://www.banfieldexchange.com/News/Genetic-risks-for-cryptorchidism
  145. https://ejournals.epublishing.ekt.gr/index.php/jhvms/article/view/15387
  146. https://pmc.ncbi.nlm.nih.gov/articles/PMC12474194/
  147. https://www.mdpi.com/2076-2615/15/21/3105
Add your contribution
Related Hubs
User Avatar
No comments yet.